Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Anlotinib in Unresectable Stage II-III NSCLC
NCT05306847Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab, anlotinib in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College Hospital. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05306847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05306847.